Figure 1. Flow of Patients Through the Trial of Blinatumomab vs Chemotherapy in Children With B-Cell Acute Lymphoblastic Leukemia (B-ALL).

Randomized patients were stratified based on age and bone marrow/minimal residual disease. M1 marrow is indicated as <5% morphologic blasts; M2 marrow, 5%-<25% morphologic blasts. Ph− indicates Philadelphia chromosome negative, ie, patients with Philadelphia chromosome were excluded.

^aData cutoff date occurred when 50% of total enrollment experienced defined study survival events. The final analysis is planned for January 2023.